הכנסות חזויות של החברה: OKYO Pharma (OKYO)

לוגו גרפי של OKYO Pharma Limited (OKYO)

OKYO Pharma Limited (OKYO) is developing advanced drops to combat neuropathy and dry eye syndrome, yet a lack of profitability and the threat of secondary offerings are creating pressure. The company's future sales metric visualizes this balance between market capture potential and development risks, where the parameter value reaches 0.00. The asset's price action relies on the medical trial cycle, rendering the stock's value independent of macroeconomic factors.

okyopharma.com - נפח מכירות צפוי של החברה OKYO (תקופה 27.06.2023 - 18.11.2026)

פילוחי מדדים פיננסיים ומדדי שוק עבור okyopharma.com (OKYO)

- שווי מניות ותחזית קונצנזוס למחירים:
- מדדי שווי החברה בבורסה:
הערכת שווי פונדמנטלית של החברה:OKYO Pharma Limited
דוגמת מוצר של OKYO Pharma Limited

OKYO Pharma Limited (OKYO) focus on the mass market for neuropathic pain therapy and ophthalmology creates a foundation for long-term growth. Analyzing the company's sales expectations, an investor sees the result of continuous discounting of future cash flows. This metric measures the market consensus regarding revenue, smoothing out reporting gaps. This allows for a real-time assessment of the impact of raw material costs on margins. The indicator's trend serves as a signal for a potential correction in capitalization.